Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
News|Videos|February 20, 2026
María Teresa Bourlon, MD, MS, FASCO, previews practice-changing research at ASCO GU 2026
Author(s)María Teresa Bourlon, MD, MS, FASCO
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.
Advertisement
Advertisement
In this preview of research expected at the 2026 ASCO Genitourinary Cancers Symposium, medical oncologist María Teresa Bourlon, MD, MS, FASCO, outlined major clinical advances anticipated across prostate, urothelial, kidney, and testicular cancers. Speaking from her practice at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, she emphasized that the meeting will focus heavily on survival outcomes, biomarker-guided therapy, and emerging treatment mechanisms.
Related to this article
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Advertisement
Advertisement